Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J E Garber

Showing results (71-80 of 79) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 79 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 17, 2018
Overexpression of BLM promotes DNA damage and increased sensitivity to platinum salts in triple-negative breast and serous ovarian cancersN J Birkbak, Y Li, S Pathania, et al.
Cancer Research|November 24, 2001
Destabilization of CHK2 by a missense mutation associated with Li-Fraumeni SyndromeS B Lee, S H Kim, D W Bell, et al.
Journal of the National Cancer Institute|May 30, 1998
Effect of smoking on breast cancer in carriers of mutant BRCA1 or BRCA2 genesJ S Brunet, P Ghadirian, T R Rebbeck, et al.
The New England Journal of Medicine|January 18, 1996
Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancerM G FitzGerald, D J MacDonald, M Krainer, et al.
Nature Medicine|November 1, 1996
Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer familiesP Tonin, B Weber, K Offit, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 17, 1998
Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer riskT S Frank, S A Manley, O I Olopade, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2017
Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II studyH S Han, V Diéras, M Robson, et al.
Journal of Medical Genetics|October 6, 2010
Germline mutations in CDH1 are infrequent in women with early-onset or familial lobular breast cancersK A Schrader, S Masciari, N Boyd, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 13, 2022
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancerC E Geyer, J E Garber, R D Gelber, et al.
Pageof 8

Showing results (71-80 of 79) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 79 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 17, 2018
Overexpression of BLM promotes DNA damage and increased sensitivity to platinum salts in triple-negative breast and serous ovarian cancersN J Birkbak, Y Li, S Pathania, et al.
Cancer Research|November 24, 2001
Destabilization of CHK2 by a missense mutation associated with Li-Fraumeni SyndromeS B Lee, S H Kim, D W Bell, et al.
Journal of the National Cancer Institute|May 30, 1998
Effect of smoking on breast cancer in carriers of mutant BRCA1 or BRCA2 genesJ S Brunet, P Ghadirian, T R Rebbeck, et al.
The New England Journal of Medicine|January 18, 1996
Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancerM G FitzGerald, D J MacDonald, M Krainer, et al.
Nature Medicine|November 1, 1996
Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer familiesP Tonin, B Weber, K Offit, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 17, 1998
Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer riskT S Frank, S A Manley, O I Olopade, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2017
Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II studyH S Han, V Diéras, M Robson, et al.
Journal of Medical Genetics|October 6, 2010
Germline mutations in CDH1 are infrequent in women with early-onset or familial lobular breast cancersK A Schrader, S Masciari, N Boyd, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 13, 2022
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancerC E Geyer, J E Garber, R D Gelber, et al.
Pageof 8